Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NRIX |
---|---|---|
09:32 ET | 15220 | 15.61 |
09:34 ET | 6079 | 15.58 |
09:36 ET | 1671 | 15.64 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Nurix Therapeutics Inc | 924.0M | -5.9x | --- |
CureVac NV | 845.6M | -2.9x | --- |
Arcutis Biotherapeutics Inc | 1.0B | -3.0x | --- |
Prothena Corporation PLC | 1.1B | -6.3x | --- |
Gyre Therapeutics Inc | 890.2M | -5.9x | --- |
SAGE Therapeutics Inc | 692.1M | -1.4x | --- |
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecules and antibody therapies based on the modulation of cellular protein levels as a treatment approach for cancer, inflammatory conditions and other diseases. It DELigase is an integrated discovery platform, to identify and advance drug candidates targeting E3 ligases. Its drug candidates include NX-2127, NX-5948 and NX-1607. NX-2127 is an orally bioavailable Brutons tyrosine kinase (BTK) degrader that also degrades cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos) for the treatment of relapsed or refractory B-cell malignancies. NX-5948 is an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and potentially autoimmune diseases. NX-1607 is an oral clinical-stage small molecule drug candidate that inhibits Casitas B-lineage lymphoma proto-oncogene-B (CBL-B).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $924.0M |
---|---|
Revenue (TTM) | $80.9M |
Shares Outstanding | 59.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.16 |
EPS | $-2.65 |
Book Value | $4.12 |
P/E Ratio | -5.9x |
Price/Sales (TTM) | 11.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -194.51% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.